Skip to content

US · MPLT · BIOTECHNOLOGY

MapLight Therapeutics, Inc. (MPLT) intrinsic value and stock valuation

$5.94as of 2026-11-21 · Mkt cap 516.45M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MapLight Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values MPLT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MPLT’s statements →

MapLight Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Redwood City, CA 94063 maplightrx.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-161.15M
20222025
Free cash flow
-$-138.61M
20222025
Total equity
$458.4M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-169.08M-$-82.95M-$-57.28M-$-31.25M
Net income-$-161.15M-$-77.58M-$-55.71M-$-30.02M
EPSd-$-3.66M-$-1.87M-$-1.34M-$-724.6K
Operating cash flow-$-138.14M-$-78.81M-$-52.01M-$-26.58M
Capital expenditure-$-470K-$-770K-$-460K-$-750K
Free cash flow-$-138.61M-$-79.58M-$-52.47M-$-27.32M
Total assets$479.5M$136.9M$91.4M$39.4M
Total debt$5.8M$6.58M$5.92M$6.27M
Net debt-$-40.93M-$-31.67M-$-73.84M-$-21.39M
Total equity$458.4M$115.2M$71.3M$20.9M
Cash and short-term investments$305.1M$108.8M$79.8M$27.7M
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$580K$700K$560K$570K
Gross profit-$-580K-$-700K-$-560K-$-570K
Research and development expenses$137.8M$67.8M$49.1M$26.6M
Selling, general and administrative expenses$30.7M$14.4M$7.61M$4.1M
Other expenses$0.00$0.00$0.00$0.00
Operating expenses$168.5M$82.3M$56.7M$30.7M
Cost and expenses$169.1M$83M$57.3M$31.3M
Interest income$5.52M$4.5M$1.1M$430K
Interest expense$0.00$0.00$0.00$0.00
Depreciation and amortization$580K$700K$560K$570K
Ebitda-$-160.57M-$-76.88M-$-55.15M-$-29.44M
Operating income-$-169.08M-$-82.95M-$-57.28M-$-31.25M
Total other income/expenses, net$7.93M$5.37M$1.57M$1.23M
Income before tax-$-161.15M-$-77.58M-$-55.71M-$-30.02M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-161.15M-$-77.58M-$-55.71M-$-30.02M
Weighted average shares outstanding$44M$41.4M$41.4M$41.4M
Weighted average diluted shares outstanding$44M$41.4M$41.4M$41.4M
Balance sheet
2025202420232022
Cash and short-term investments$305.1M$108.8M$79.8M$27.7M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$324.7M$114.6M$83.6M$32M
Property, plant and equipment, net$6.58M$7.56M$6.58M$7.12M
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$148.2M$11.6M$1.22M$230K
Total non-current assets$154.8M$22.3M$7.8M$7.36M
Total assets$479.5M$136.9M$91.4M$39.4M
Accounts payable$0.00$1.91M$3.25M$3.6M
Short-term debt$890K$780K$490K$350K
Deferred revenue$0.00$3.24M$4.2M$5.86M
Total current liabilities$16.2M$15.9M$14.7M$12.6M
Long-term debt$4.91M$5.8M$5.43M$5.92M
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$4.91M$5.8M$5.43M$5.92M
Capital lease obligations$4.91M$5.8M$5.43M$5.92M
Total liabilities$21.1M$21.7M$20.1M$18.5M
Common stock$10K$0.00$0.00$0.00
Retained earnings-$-360.52M-$-199.37M-$-121.79M-$-66.08M
Accumulated other comprehensive income (loss)-$-230K$160K$0.00$0.00
Total equity$458.4M$115.2M$71.3M$20.9M
Total investments$406.6M$82.1M$1.22M$230K
Total debt$5.8M$6.58M$5.92M$6.27M
Net debt-$-40.93M-$-31.67M-$-73.84M-$-21.39M
Cash flow statement
2025202420232022
Net income-$-161.15M-$-77.58M-$-55.71M-$-30.02M
Depreciation and amortization$580K$700K$560K$570K
Stock-based compensation$0.00$0.00$0.00$0.00
Change in working capital-$-12.84M-$-3.06M$2.04M$1.72M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-138.14M-$-78.81M-$-52.01M-$-26.58M
Investments in property, plant and equipment-$-470K-$-770K-$-460K-$-750K
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-323.21M-$-80.79M-$-460K-$-750K
Common stock issued$474.8M$120.3M$104.6M$33.2M
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$469.8M$118.1M$104.6M$33.2M
Net change in cash$8.48M-$-41.52M$52.1M$27.7M
Cash at end of period$46.7M$38.3M$79.8M$27.7M
Operating cash flow-$-138.14M-$-78.81M-$-52.01M-$-26.58M
Capital expenditure-$-470K-$-770K-$-460K-$-750K
Free cash flow-$-138.61M-$-79.58M-$-52.47M-$-27.32M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MapLight Therapeutics, Inc.

        MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.

        CEO
        Christopher A. Kroeger
        Employees
        133
        Beta
        2.65

        Explore

        Frequently asked questions

        What is the intrinsic value of MapLight Therapeutics, Inc. (MPLT)?

        InvestorsCraft does not currently publish an intrinsic value for MPLT. How the IC value is calculated.

        Is MPLT undervalued?

        InvestorsCraft does not publish an undervaluation signal for MPLT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.